Organigram Global Inc. (OGI) closed its acquisition of Sanity Group GmbH on April 15, 2026, in a transaction valued at up to €250 million. The deal consists of an upfront payment of €130 million—comprising €107.3 million in cash and €22.7 million in OGI shares—plus a potential earnout of up to €120 million, or alternatively €107.3 million upfront (cash €78.0 million and shares €29.3 million) with an earnout of up to €113.8 million. Financing was secured through a private placement with BT DE Investments Inc., a subsidiary of British American Tobacco, and senior secured credit facilities with ATB Financial.
Sanity Group operates across Germany, Switzerland, the United Kingdom, Poland, and the Czech Republic, and reported revenue growth from €9 million in 2023 to €61 million in 2025, with gross margins expanding from 14.5 % to 47.2 %. The company generated positive EBITDA in 2025, underscoring its profitability and making it an attractive acquisition target for a company seeking to strengthen its medical cannabis portfolio.
The acquisition expands OGI’s medical cannabis presence into Germany, Austria, and Switzerland, diversifying the company’s revenue streams beyond Canada’s saturated recreational market. By adding Sanity Group’s established production facilities, distribution network, and customer contracts, OGI gains immediate scale and regulatory expertise in a rapidly growing European market, positioning it to capture new approvals and accelerate international sales growth.
James Yamanaka, CEO of Organigram, said the deal "marks a pivotal step in Organigram's global expansion strategy as a leader in the rapidly expanding cannabis industry." Paolo De Luca, Chief Strategy Officer, added that the transaction is "both strategically significant and financially accretive" and will "accelerate growth in key European markets."
Institutional Shareholder Services (ISS) recommended shareholders vote in favor of the acquisition, citing a compelling strategic rationale, increased scale, geographic diversification, and improved cash flow. ISS noted that the premium financing by BAT signals strong institutional confidence and a long‑term strategic alignment, reinforcing the positive market perception of the deal.
Prior to the acquisition, OGI’s Q1 Fiscal 2026 results showed net revenue of $63.5 million, a 49 % year‑over‑year increase, and a net income of $20 million versus a net loss of $27.5 million in Q1 Fiscal 2025. The acquisition is expected to be accretive, leveraging Sanity Group’s positive EBITDA and high‑margin medical product mix to enhance OGI’s overall profitability and support its goal of higher‑margin medical exports.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.